Chemical proteasome inhibition as a novel animal model of inner retinal degeneration in rats

PLoS One. 2019 May 31;14(5):e0217945. doi: 10.1371/journal.pone.0217945. eCollection 2019.

Abstract

Chemical proteasome inhibition has been a valuable animal model of neurodegeneration to uncover roles for the ubiquitin-proteasome system in the central nervous system. However, little is known about the effects of chemical proteasome inhibitors on retinal integrity. Therefore, we characterized the effects of structurally different chemical proteasome inhibitors on the retinal morphology and the mechanisms of their action in the normal adult rat eyes. Intravitreal injection of MG-262 and other proteasome inhibitors led to inner retinal degeneration. MG-262-induced inner retinal degeneration was accompanied by reduced proteasome activity, increased poly-ubiquitinated protein levels, and increased positive immunostaining of ubiquitin, 20S proteasome subunit and GADD153/CHOP in the retina. Its retinal degenerative effect was also associated with reduced retinal neurofilament light chain gene expression, reflecting retinal ganglion cell death. MG-262-induced neurofilament light chain downregulation was largely resistant to pharmacological modulation including endoplasmic reticulum stress, apoptosis or MAP kinase inhibitors. Thus, this study provides further evidence of roles for the ubiquitin-proteasome system in the maintenance of the retinal structural integrity. Chemical proteasome inhibition may be used as a novel animal model of inner retinal degeneration, including retinal ganglion cell loss, which warrants further analysis of the molecular mechanisms underlying its retinal degenerative effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Boronic Acids / adverse effects
  • Boronic Acids / pharmacology
  • Disease Models, Animal
  • Endoplasmic Reticulum / drug effects
  • Endoplasmic Reticulum Stress / drug effects
  • Humans
  • Proteasome Endopeptidase Complex / drug effects
  • Proteasome Endopeptidase Complex / genetics*
  • Proteasome Inhibitors / pharmacology*
  • Rats
  • Retina / drug effects
  • Retina / pathology*
  • Retinal Degeneration / chemically induced
  • Retinal Degeneration / metabolism
  • Retinal Degeneration / pathology*
  • Retinal Ganglion Cells / drug effects
  • Retinal Ganglion Cells / pathology
  • Thapsigargin / adverse effects
  • Thapsigargin / pharmacology
  • Tunicamycin / adverse effects
  • Tunicamycin / pharmacology

Substances

  • Boronic Acids
  • MG 262
  • Proteasome Inhibitors
  • Tunicamycin
  • Thapsigargin
  • Proteasome Endopeptidase Complex

Grants and funding

Santen Pharmaceutical Co. Ltd provided support in the form of salaries for all of the authors, but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.